Contact
searchSearch
HMP Global
Login

FGFR Videos

Vivek Subbiah, MD, Sarah Cannon Research Institute
Videos
Management of Adverse Events Associated With FGFR Inhibitors
12/12/2023
Vivek Subbiah, MD, discusses the management of adverse events associated with FGFR inhibitors for urothelial carcinoma and cholangiocarcinoma.
Vivek Subbiah, MD, discusses the management of adverse events associated with FGFR inhibitors for urothelial carcinoma and cholangiocarcinoma.
Vivek Subbiah, MD, discusses the...
12/12/2023
Oncology
Antoni Vilaseca, MD, Hospital Clínic de Barcelona
Videos
Novel Erdafitinib Intravesical Delivery System Showed Safety, Efficacy for Patients With Non–Muscle-Invasive Bladder Cancer With Select FGFR Alterations
11/01/2023
Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.
Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.
Antoni Vilaseca, MD, discusses...
11/01/2023
Oncology
Vivek Subbiah, MD, MD Anderson Cancer Center
Videos
Next Steps for Pemigatinib on FGFR Inhibition With Multiple Tumors, FDA Approval
04/11/2022
Vivek Subbiah, MD, University of Texas, shares updates of pemigatinib in the upcoming FIGHT-302 study and highlights how an FDA approval will benefit patients with CCA harboring an FGFR2 mutation.
Vivek Subbiah, MD, University of Texas, shares updates of pemigatinib in the upcoming FIGHT-302 study and highlights how an FDA approval will benefit patients with CCA harboring an FGFR2 mutation.
Vivek Subbiah, MD, University of...
04/11/2022
Oncology
Vivek Subbiah, MD, MD Anderson Cancer Center
Videos
Pemigatinib Safe, Demonstrates Encouraging Responses Among Patients With Advanced Malignancies and an FGFR Mutation: FIGHT-101 Trial
04/01/2022
Vivek Subbiah, MD, University of Texas, overviews the FIGHT-101 trial on pemigatinib, a selective FGFR 1-3 inhibitor, which targets mutations across a variety of tumor types.
Vivek Subbiah, MD, University of Texas, overviews the FIGHT-101 trial on pemigatinib, a selective FGFR 1-3 inhibitor, which targets mutations across a variety of tumor types.
Vivek Subbiah, MD, University of...
04/01/2022
Oncology
Dr Azab
Videos
Bone Marrow as a Tool to Predict Response to Therapy for MM
02/16/2022
Kareem Azab, PhD, discusses 3D tissue-engineered bone marrow as a tool to predict patient responses to therapy for MM.
Kareem Azab, PhD, discusses 3D tissue-engineered bone marrow as a tool to predict patient responses to therapy for MM.
Kareem Azab, PhD, discusses 3D...
02/16/2022
Oncology
.
Videos
Dr Shah Discusses HER-RAM Study Results in HER2+ GI Cancers
06/15/2021
Manish Shah, MD, highlights findings from the phase 1b/2 HER-RAM study. These data were presented at the 2021 ASCO Annual Meeting.
Manish Shah, MD, highlights findings from the phase 1b/2 HER-RAM study. These data were presented at the 2021 ASCO Annual Meeting.
Manish Shah, MD, highlights...
06/15/2021
Oncology

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use